Lys 199 mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists
Restricted accessOtherFirst published online September, 2000
Lys 199 mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists
Many slow dissociating (insurmountable) non-peptide angiotensin type 1 receptor (AT1) antagonists contain, besides the acidic biphenyltetrazole substructure of losartan, a second acidic group to stabilise antagonist-receptor complexes. To investigate the involved basic amino-acids of the human AT1-receptor, wild-type and mutant receptors were transiently transfected in CHO-K1 cells and characterised by [3H]candesartan binding. Lys199 → Gln substitution decreased the affinity 45-fold for candesartan (95% insurmountable), 18-fold for EXP3174 (70% insurmountable), 10-fold for irbesartan (40% insurmountable) and 5-fold for losartan (surmountable). His256 → Ala substitution had only minor effects. This suggests that Lys199 is important for the tight binding of non-peptide antagonists.
Liu YJ, Shankley NP, Welsh NJ, Black JWEvidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action. Br J Pharmacol1992; 106: 233-41.
2.
Cazaubon C., Gougat J., Bousquet F. et al. Pharmacological characterization of SR 47436, a new non-peptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther1993; 265: 826-34.
3.
Noda M., Shibouta Y., Inada Y. et al. Inhibition of rabbit aoritc angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem Pharmacol1993; 46: 311-8.
4.
MochizukiS,Sato T., Furata K. et al. Pharmacological properties of KT3-671, a novel non-peptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol1995; 25: 22-9.
5.
Vanderheyden P., Fierens FLP, De Backer J.-P, Frayman N., Vauquelin G.Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. Brit J Pharmacol1999; 126:1057-65.
6.
Fierens FLP , Vanderheyden PML , De Backer J.-P. Vauquelin G. Insurmountable angiotensin II AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol1999; 372: 199-206.
7.
Fierens FLP , Vanderheyden PML , De Backer J.-P. Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol1999; 367: 413-22.
8.
Shibouta Y., Inada Y., Ojima M. et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]1Hbenzimidazole-7-carboxylic acid (CV11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther1993; 266: 114-20.
9.
Wong PC, Price WA, Chiu AT et al. Non-peptide angiotensin II receptor antagonists. IX. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1990; 255: 211-7.
10.
Cheng YC, Prusoff WHRelationship between the inhibition constant (Ki) and the concentration of inhibitor wich causes 50% inhibition (IC50) of an enzymatic reaction. Mol Pharmacol1973; 32: 2497-503.
11.
Morsing P.,Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension1999; 33: 1406-13.
12.
Vanderheyden PML , Verheijen I., Fierens FLP, De Backer JP, Vauquelin G.Binding characteristics of [3H]irbesartan to human recombinant angiotensin type 1 receptors. JRAAS2000; 1:159-65.
13.
Inoue Y., Nakamura N Inagami T.A review of mutagenesis studies on angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism, J Hypertens1997; 15: 703-714.
14.
Mirua SI, Feng Y.-H, Huasain A., Karnik SSRole of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem1999; 274: 7103-10.
15.
Noda K., Saad, Y.,Kinoshita, A. et al.Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same sub-site by different mechanisms.JBiol Chem1995; 270: 2284-9.
16.
Noda K., Saad Y., Karnik SSInteraction of Phe8 of angiotensin II with Lys199 and His 256 of AT1 receptor in agonist activation.JBiol Chem1995; 270: 28511-4.
17.
Monnot C., Bihoreau C., Conchon S., Curnow KM, Corvol P., Clauser E.Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem1996; 271: 1507-13.
18.
Yamano Y., Ohyama K., Kikyo M. et al. Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem1995; 270:14024-30.
19.
Schambye HT , Hjorth SA, Bergsma DJ, Sathe G., Schwartz TWDifferentiation between binding sites for angiotensin II and non-peptide antagonists on the angiotensin II type 1 receptors . Proc Natl Acad Sci USA1994; 91: 7046-50.
20.
Duncia JV, Chiu AT, Carini DJ et al.The discovery of potent non-peptide angiotensin II receptors antagonists: a new class of potent antihypertensives. J Med Chem1990; 33: 1312-29.
21.
Timmermans Pbwm, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev1993 ; 45: 205-51.
22.
Robertson MJ , Barnes JC, Drew GM et al. Pharmacological profile of GR 117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol1992 ; 107: 1173-80.
23.
Criscione L. , de Gasparo M., Bühlmayer P., Whitebread S., Ramjoué HP, Wood J.Pharmacological profile of valsartan: a potent, orally active, non-peptide antagonist of the angiotensin II AT1 receptor subtype . Br J Pharmacol1993; 110: 761-71.
24.
Dickinson KE , Cohen RB, Skwish S. et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174 . Br J Pharmacol1994; 113: 179-89.
25.
Renzetti A. , Cucci P., Guelfi M., Cirillo R., Salimbeni A., Giachetti A.Pharmacology of LR-B/057, a novel orally active AT1 receptor antagonist. J Cardiovasc Pharmacol1995; 25:354-60.
26.
Panek RL, Lu GH, Overhisser RW, Major TC, Hodges JC, Taylor DGFunctional studies but not receptor binding can distinguish surmountable from insurmountable ATl antagonism. J Pharm Exp Ther1995; 273: 753-61.
27.
De Arriba AF , Gomez-Casajus LA, Cavalcanti F., Almansa C., Garcia-Rafanel J., Forn J., In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR7280 . Eur J Pharmacol1996; 318: 341-7.
28.
Tamura K., Okuhira M., Mikoshiba I., Hashimoto K.In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharmacol Bull1997; 20: 850-5.
29.
Reitz DB, Garland DJ, Norton MB et al. N1-sterically hindered 2H-imidazole-2-one angiotensin II receptor antagonists: the conversion of surmountable antagonists into insurmountable antagonists. Biorg Med Chem Lett1993; 3: 1055-60.
30.
Vauquelin G. , Morsing P., Fierens FLP, De Backer JP, Vanderheyden PMLA two-state receptor model for the interaction between angiotensin II AT1 receptors and their non-peptide antagonists. Biochem Pharmacol2000; (accepted).
